Literature DB >> 9551611

High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression.

J M Howell1, H Lochmüller, A O'Hara, S Fletcher, B A Kakulas, B Massie, J Nalbantoglu, G Karpati.   

Abstract

Replication-deficient adenovirus vectors (AdV) have been successfully used to transfer a truncated human dystrophin cDNA to skeletal muscle of dystrophin-deficient mdx mice. A dystrophin-deficient golden retriever dog model (GRMD) has been identified, which, unlike the mouse model, leads to a clinicopathological phenotype similar to that of Duchenne muscular dystrophy (DMD). We show for the first time that high-level dystrophin expression in skeletal muscle of GRMD dogs can be achieved by AdV-mediated gene transfer. However, a humoral and cellular immune response of the host against antigens of viral and transgene origin (similar to that occurring in mdx mice after AdV-mediated dystrophin gene transfer) leads to a decline of dystrophin expression over a 2-month period. Immunosuppression by cyclosporin significantly prolonged transgene expression. The GRMD model may help to solve the open questions pertaining to dystrophin gene transfer such as systemic delivery and improvement of muscle function before human trials for gene replacement therapy in DMD may be considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551611     DOI: 10.1089/hum.1998.9.5-629

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  18 in total

1.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

Review 3.  Strategies to modulate immune responses: a new frontier for gene therapy.

Authors:  Valder R Arruda; Patricia Favaro; Jonathan D Finn
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

Review 4.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

Review 5.  Gene therapies in canine models for Duchenne muscular dystrophy.

Authors:  Peter P Nghiem; Joe N Kornegay
Journal:  Hum Genet       Date:  2019-02-07       Impact factor: 4.132

6.  Migration of dendritic cells from murine skeletal muscle.

Authors:  Lei Wang; Saman Eghtesad; Paula R Clemens
Journal:  Immunobiology       Date:  2010-05-21       Impact factor: 3.144

7.  Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS.

Authors:  Hubert Dabiré; Inès Barthélémy; Nicolas Blanchard-Gutton; Lucien Sambin; Carolina Carlos Sampedrano; Vassiliki Gouni; Yves Unterfinger; Pablo Aguilar; Jean-Laurent Thibaud; Bijan Ghaleh; Alain Bizé; Jean-Louis Pouchelon; Stéphane Blot; Alain Berdeaux; Luc Hittinger; Valérie Chetboul; Jin Bo Su
Journal:  Basic Res Cardiol       Date:  2011-12-23       Impact factor: 17.165

Review 8.  Duchenne muscular dystrophy gene therapy in the canine model.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-24       Impact factor: 5.032

Review 9.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 10.  Therapeutic approaches to muscular dystrophy.

Authors:  Aurélie Goyenvalle; Jane T Seto; Kay E Davies; Jeffrey Chamberlain
Journal:  Hum Mol Genet       Date:  2011-03-24       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.